Table 2 Therapy and prognosis of study participants stratified by HRCT pattern
| Â | Â | HRCT pattern | ||||||
|---|---|---|---|---|---|---|---|---|
Total | OP | NSIPÂ +Â OP | NSIP | |||||
Number of patients, n | 98 | 20 | 15 | 63 | ||||
5-year survival, % | 71.1% | 100.0% | 86.7% | 58.6% | ||||
Treatment,n (%) | 78 | (79.6%) | 19 | (95%) | 15 | (100%) | 44 | (69.8%) |
 corticosteroid, n(%) | 17 | (17.3%) | 15 | (75%) | 6 | (40%) | 6 | (9.5%) |
 corticosteroid + ISa, n (%) | 48 | (49.0%) | 4 | (20%) | 9 | (60%) | 35 | (55.6%) |
 corticosteroid + IS + pirfenidone, n (%) | 1 | (1.0%) | 0 | (0%) | 0 | (0%) | 1 | (1.6%) |
 pirfenidone, n (%) | 2 | (2.0%) | 0 | (0%) | 0 | (0%) | 2 | (3.2%) |
Response to Treatment, n (%) | 70 | (71.4%) | 19 | (95%) | 15 | (100%) | 36 | (57.1%) |
 Improve/stable/deteriorate, n | 45/20/5 | 18/1/0 | 14/1/0 | 13/18/5 | ||||
Overall death, n (%) | 27 | (27.6%) | 1 | (5%) | 3 | (20%) | 23 | (36.5%) |
Death due to respiratory failure, n (%) | 15 | (15.3%) | 0 | (0%) | 1 | (6.7%) | 14 | (22.2%) |
 Acute exacerbation, n (%) | 5 | (5.1%) | 0 | (0%) | 0 | (0%) | 5 | (7.9%) |